TW202216172A - 治療血友病之方法及組成物 - Google Patents

治療血友病之方法及組成物 Download PDF

Info

Publication number
TW202216172A
TW202216172A TW110122791A TW110122791A TW202216172A TW 202216172 A TW202216172 A TW 202216172A TW 110122791 A TW110122791 A TW 110122791A TW 110122791 A TW110122791 A TW 110122791A TW 202216172 A TW202216172 A TW 202216172A
Authority
TW
Taiwan
Prior art keywords
patient
hemophilia
fituslan
inhibitor
qol
Prior art date
Application number
TW110122791A
Other languages
English (en)
Chinese (zh)
Inventor
柏松 梅
蕭納 安德森
旗峰 俞
普羅納貝席 達斯瑪哈帕特拉
Original Assignee
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健臻公司 filed Critical 美商健臻公司
Publication of TW202216172A publication Critical patent/TW202216172A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW110122791A 2020-06-22 2021-06-22 治療血友病之方法及組成物 TW202216172A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042390P 2020-06-22 2020-06-22
US63/042,390 2020-06-22

Publications (1)

Publication Number Publication Date
TW202216172A true TW202216172A (zh) 2022-05-01

Family

ID=76943130

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110122791A TW202216172A (zh) 2020-06-22 2021-06-22 治療血友病之方法及組成物

Country Status (12)

Country Link
US (2) US20210393669A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168018A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531679A (cg-RX-API-DMAC7.html)
KR (1) KR20230027277A (cg-RX-API-DMAC7.html)
CN (3) CN115942940A (cg-RX-API-DMAC7.html)
AU (1) AU2021296786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188137A1 (cg-RX-API-DMAC7.html)
IL (1) IL299295A (cg-RX-API-DMAC7.html)
MX (1) MX2023000164A (cg-RX-API-DMAC7.html)
TW (1) TW202216172A (cg-RX-API-DMAC7.html)
WO (1) WO2021262695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CA3258531A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation TREATMENT OF HEMOPHILIA WITH FITUSIRAN
CN118460655B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团(天津)股份有限公司 抑制FXI基因表达的siRNA的制备方法
TW202610665A (zh) * 2024-07-10 2026-03-16 大陸商正大天晴藥業集團股份有限公司 靶向serpinc1的雙鏈核糖核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Also Published As

Publication number Publication date
EP4168018A1 (en) 2023-04-26
CN122124087A (zh) 2026-06-02
JP2023531679A (ja) 2023-07-25
IL299295A (en) 2023-02-01
CA3188137A1 (en) 2021-12-30
MX2023000164A (es) 2023-07-06
US20260014188A1 (en) 2026-01-15
WO2021262695A1 (en) 2021-12-30
BR112022026265A2 (pt) 2023-01-17
CN122005597A (zh) 2026-05-12
CN115942940A (zh) 2023-04-07
KR20230027277A (ko) 2023-02-27
AU2021296786A1 (en) 2023-02-23
US20210393669A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US20260014188A1 (en) Methods and compositions for treating hemophilia
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
US20240027478A1 (en) Treatment of hemophilia with fitusiran
TW202417014A (zh) 於小兒患者中以非妥西蘭治療血友病
KR20250024800A (ko) A형 및 b형 혈우병의 치료를 위한 피투시란
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
EP2349288A2 (en) Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
CN116723863A (zh) 用于治疗出血性病症的组合物和方法
CN118434425A (zh) 用于改善血友病患者的患者报告结局的非妥西兰
CN116635040A (zh) 用非妥西兰治疗血友病